Bladder Cancer - Results from #140

Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel. October 1, 2024

Prognostic Nomogram, Demographics and Comparative Analysis of Urinary Bladder Small Cell and Large Cell Neuroendocrine Carcinoma. October 1, 2024

Adjuvant radiation therapy for locally advanced bladder cancer: A safe and promising emerging treatment option September 30, 2024

Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value. September 30, 2024

Risk of Progression of High-grade Primary T1 Non-muscle-invasive Bladder cancer in a Contemporary Cohort. September 30, 2024

MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle-invasive bladder cancer. September 30, 2024

Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer. September 30, 2024

Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. September 27, 2024

Bladder cancer incidence and mortality among men with and without castration therapy for prostate cancer - a nation-wide cohort study. September 27, 2024

Improved bladder diagnostics using multiparametric ultrasound. September 27, 2024

The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee. September 26, 2024

An overview of immune checkpoint inhibitor toxicities in bladder cancer. September 26, 2024

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States. September 25, 2024

Clinical use of nadofaragene firadenovec-vncg. September 25, 2024

Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial. September 24, 2024

Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer. September 24, 2024

Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review. September 23, 2024

HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer. September 23, 2024

APPRAISE-AI Tool for Quantitative Evaluation of AI Studies for Clinical Decision Support. September 21, 2024

TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. September 21, 2024

Page 8 of 522